Impact of premorbid hypertension and renin-angiotensin-aldosterone system inhibitors on the severity of aneurysmal subarachnoid haemorrhage: a multicentre study
Zhong P, Lu Z, Li Z, Li T, Lan Q, Liu J, Chen S, Wang Z, Huang Q. Impact of premorbid hypertension and renin-angiotensin-aldosterone system inhibitors on the severity of aneurysmal subarachnoid haemorrhage: a multicentre study. Stroke And Vascular Neurology 2024, 10: e003052. PMID: 38889918, PMCID: PMC12107460, DOI: 10.1136/svn-2023-003052.Peer-Reviewed Original ResearchRenin-angiotensin-aldosterone systemWorld Federation of Neurological SurgeonsAneurysmal subarachnoid haemorrhageRenin-angiotensin-aldosterone system inhibitorsHunt-Hess scaleClinical grading scaleClinical outcomesUncontrolled hypertensionGrading scaleWorld Federation of Neurological Surgeons scaleRisk of adverse clinical outcomesHypertension statusElevated risk of poor outcomesSubarachnoid haemorrhageRisk of adverse outcomesComparison to patientsAdverse clinical outcomesRisk of poor outcomesNormal blood pressureMultivariate logistic regressionIntracranial aneurysm ruptureRisk of intracranial aneurysm rupturePremorbid hypertensionSystem inhibitorsMulticentre studyPredictors of Disease Progression and Adverse Clinical Outcomes in Patients With Moderate Aortic Stenosis Using an Artificial Intelligence-Based Software Platform
Salem M, Gada H, Ramlawi B, Sotelo M, Nona P, Wagner L, Rogers C, Brigman L, Vora A. Predictors of Disease Progression and Adverse Clinical Outcomes in Patients With Moderate Aortic Stenosis Using an Artificial Intelligence-Based Software Platform. The American Journal Of Cardiology 2024, 223: 92-99. PMID: 38710350, DOI: 10.1016/j.amjcard.2024.04.051.Peer-Reviewed Original ResearchConceptsAdverse clinical outcomesRisk of adverse clinical outcomesModerate aortic stenosisClinical outcomesAortic stenosisDisease progressionSevere ASModerate ASAtrial fibrillationAmerican Heart Association/American College of Cardiology guidelinesLower left ventricular ejection fractionAssociated with adverse clinical outcomesPredictor of clinical outcomePredictors of disease progressionAmerican Heart Association/American CollegeFactors associated with outcomesVentricular ejection fractionEnd-stage renal diseaseHeart failure hospitalizationCox proportional hazards modelsProportional hazards modelSerial echoesAS severityEjection fractionCardiology guidelinesDapagliflozin and Timing of Prior Heart Failure Hospitalization A Patient-Level Meta-Analysis of DAPA-HF and DELIVER
Butt J, Jhund P, Docherty K, Claggett B, Vaduganathan M, Bachus E, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Solomon S, McMurray J. Dapagliflozin and Timing of Prior Heart Failure Hospitalization A Patient-Level Meta-Analysis of DAPA-HF and DELIVER. JACC Heart Failure 2024, 12: 1586-1599. PMID: 38573262, DOI: 10.1016/j.jchf.2024.01.018.Peer-Reviewed Original ResearchConceptsHF hospitalizationDAPA-HFHeart failureComposite of worsening HFPrimary outcomePatient-level pooled analysisRisk of adverse clinical outcomesBenefits of dapagliflozinMedian Follow-UpMonths of randomizationEffects of dapagliflozinAdverse clinical outcomesPrior HF hospitalizationHospital categoryPrimary endpointPrevent 1 eventClinical outcomesAbsolute benefitEffective therapyFollow-upCardiovascular deathDapagliflozinAssociated with timeHigh riskPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply